Breaking News Instant updates and real-time market news.

2023-01-23 08:17:16 ALE Allete $64.17 / +0.665 (+1.05%) 08:17 01/23/23 01/23 08:17 01/23/23 08:17	Allete downgraded to Sell from Neutral at Guggenheim Guggenheim analyst Shahriar Pourreza downgraded Allete to Sell from Neutral with a price target of $54, up from $53.	16 Feb 01 Apr

2023-01-23 08:17:16

ALE

Allete

$64.17 / +0.665 (+1.05%)

08:17

01/23/23

01/23

08:17

01/23/23

08:17

Allete downgraded to Sell from Neutral at Guggenheim

Guggenheim analyst Shahriar Pourreza downgraded Allete to Sell from Neutral with a price target of $54, up from $53.

16
Feb

01
Apr

OTHER BREAKING NEWS FROM THE FLY

Upgrade	H.B. Fuller upgraded to Buy from Neutral at Citi » 05:58 02/03/23 02/03 05:58 02/03/23 05:58 FUL H.B. Fuller $73.22 / +2.91 (+4.14%) Citi analyst Eric Petrie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 09/26/22 H.B. Fuller names Celeste Mastin as new CEO 09/21/22 H.B. Fuller narrows FY22 adjusted EBITDA view to $540M-$550M from $530M-$550M FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/23/23 Citi H.B. Fuller price target raised to $72 from $65 at Citi 01/20/23 Deutsche Bank H.B. Fuller price target raised to $78 from $72 at Deutsche Bank 01/20/23 Baird H.B. Fuller price target lowered to $80 from $85 at Baird 10/13/22 Baird H.B. Fuller margins biased higher despite macro evironment, says Baird FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/18/23 H.B. Fuller sees FY23 adjusted EPS $4.15-$4.55, consensus $4.63 01/18/23 H.B. Fuller reports Q4 adjusted EPS $1.04, consensus $1.24 09/21/22 H.B. Fuller sees Q4EPS $1.15-$1.30, consensus $1.28 09/21/22 H.B. Fuller reports Q3 EPS $1.06, consensus $1.04 FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/18/23 Fly Intel: After-Hours Movers 09/22/22 What You Missed On Wall Street This Morning 09/22/22 Fly Intel: Pre-market Movers 09/21/22 Fly Intel: After-Hours Movers
Hot Stocks	XPeng launches G9 SUV, P7 sports sedan in European markets » 05:57 02/03/23 02/03 05:57 02/03/23 05:57 XPEV XPeng $11.05 / -0.09 (-0.81%) XPeng launched its two… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XPEV XPeng $11.05 / -0.09 (-0.81%) 02/01/23 XPeng delivers 5,218 Smart EVs in January 01/06/23 XPeng falls -15.8% 01/06/23 XPeng falls -16.1% 01/06/23 XPeng falls -11.3% XPEV XPeng $11.05 / -0.09 (-0.81%) 01/11/23 JPMorgan XPeng downgraded to Neutral from Overweight at JPMorgan 01/06/23 BofA XPeng downgraded to Neutral at BofA after Tesla price cuts 01/06/23 BofA XPeng downgraded to Neutral from Buy at BofA 01/04/23 Wedbush Demand issues, Twitter focus creates 'perfect storm' for Tesla, says Wedbush XPEV XPeng $11.05 / -0.09 (-0.81%) 11/30/22 XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B 11/30/22 XPeng reports Q3 EPS (36c), consensus (36c) 08/23/22 XPeng sees Q3 revenue RMB6.8B-RMB7.2B, up 18.9%-25.9% from last year 08/23/22 XPeng reports Q2 no-GAAP EPS (43c), consensus ($2.61) XPEV XPeng $11.05 / -0.09 (-0.81%) 01/17/23 XPeng follows Tesla with price cuts in China, Reuters reports 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports XPEV XPeng $11.05 / -0.09 (-0.81%) 01/17/23 What You Missed On Wall Street On Tuesday 01/17/23 What You Missed On Wall Street This Morning 01/17/23 What You Missed This Week in EVs and Clean Energy 01/17/23 Fly Intel: Pre-market Movers XPEV XPeng $11.05 / -0.09 (-0.81%) 01/30/23 XPeng call volume above normal and directionally bullish 01/27/23 XPeng call volume above normal and directionally bullish 01/24/23 XPeng call volume above normal and directionally bullish 01/23/23 XPeng call volume above normal and directionally bullish
Downgrade	Repare Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 01/19/23 Repare Therapeutics receives $1.5M payment from Ono Pharmaceuticals RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/17/22 H.C. Wainwright Repare Therapeutics price target lowered to $25 from $38 at H.C. Wainwright 06/06/22 H.C. Wainwright Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 04/12/22 Stifel Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis' RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/09/22 Repare Therapeutics reports Q3 EPS $1.71, consensus (89c)
General news	Energy Action: » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 $ECON Economic Data / + Energy Action: Oil prices… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Periodicals On The Fly $ECON Economic Data / + $ECON Economic Data / + 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says 01/22/23 Fed sets course for milder interest-rate rise next month, WSJ says 11/04/22 Fed's Evans says smaller rate hikes make sense, Reuters reports 10/22/22 Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says $ECON Economic Data / + 02/01/23 What You Missed On Wall Street On Wednesday 01/24/23 What You Missed On Wall Street On Tuesday 01/18/23 What You Missed On Wall Street On Wednesday 12/15/22 What You Missed On Wall Street On Thursday
Upgrade	Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley » 05:54 02/03/23 02/03 05:54 02/03/23 05:54 NBIX Neurocrine $107.96 / -2.045 (-1.86%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBIX Neurocrine $107.96 / -2.045 (-1.86%) 01/09/23 Xenon Pharmaceuticals outlines key milestone opportunities for 2023 01/09/23 Voyager, Neurocrine enter collaboration to advance multiple gene therapies 12/22/22 Neurocrine: FDA accepts sNDA for valbenazine 12/06/22 Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2 NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/13/22 RBC Capital Neurocrine CAH data appears pushed back, says RBC Capital 11/14/22 Evercore ISI Neurocrine downgraded to In Line from Outperform at Evercore ISI 11/02/22 BMO Capital Neurocrine price target raised to $101 from $78 at BMO Capital 11/02/22 Wells Fargo Neurocrine price target raised to $120 from $110 at Wells Fargo NBIX Neurocrine $107.96 / -2.045 (-1.86%) 11/01/22 Neurocrine reports Q3 non-GAAP EPS $1.08, consensus 79c 08/04/22 Neurocrine reports Q2 non-GAAP EPS 84c, consensus 15c NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/06/22 Fly Intel: After-Hours Movers 09/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/06/23 Biotech Ski Summit 02/06/23 Neurocrine - NBIX
Downgrade	Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 IMRX Immuneering $4.16 / +0.05 (+1.22%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/28/22 Immuneering doses first patient in Phase 1/2a trial of IMM-1-104 11/10/22 Immuneering presents preclinical data on its second program IMM-6-415 10/20/22 Immuneering names Leah Neufeld as Chief People Officer 09/30/22 Immuneering: FDA clears IND for Phase 1/2a clinical trial of IMM-1-104 IMRX Immuneering $4.16 / +0.05 (+1.22%) 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 09/30/22 Piper Sandler Immuneering transitions to clinical stage with IND approval, says Piper Sandler 07/25/22 Piper Sandler Immuneering CFO departure not a 'red flag,' says Piper Sandler 07/08/22 Chardan Immuneering initiated with a Buy at Chardan IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/10/22 Immuneering expects FY22 GAAP operating expenses $53M-$56M 11/10/22 Immuneering reports Q3 EPS (49c), consensus (49c)
Earnings	Sanofi sees 2023 business EPS up at low single digit rate at CER » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 SNY Sanofi $47.22 / -1.505 (-3.09%) Sanofi expects 2023… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 05:52 Today Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Esperion upgraded to Equal Weight from Underweight at Morgan Stanley » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 ESPR Esperion $5.91 / -0.49 (-7.66%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ESPR Esperion $5.91 / -0.49 (-7.66%) 01/11/23 RFK Racing enters team-wide partnership with Esperion 12/07/22 Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL 11/16/22 Esperion promotes Ben Halladay to CFO role 08/26/22 Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force ESPR Esperion $5.91 / -0.49 (-7.66%) 12/07/22 H.C. Wainwright H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint 08/03/22 Credit Suisse Esperion downgraded to Underperform from Neutral at Credit Suisse 05/04/22 JPMorgan Esperion upgraded to Neutral on achievable estimates at JPMorgan 05/04/22 JPMorgan Esperion upgraded to Neutral from Underweight at JPMorgan ESPR Esperion $5.91 / -0.49 (-7.66%) 01/08/23 Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M 11/01/22 Esperion reports Q3 EPS (81c), consensus (92c) ESPR Esperion $5.91 / -0.49 (-7.66%) 12/09/22 Biotech Alert: Searches spiking for these stocks today 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ESPR Esperion $5.91 / -0.49 (-7.66%) 01/06/23 Esperion call volume above normal and directionally bullish 12/19/22 Esperion put volume heavy and directionally bearish 12/07/22 Unusually active option classes on open December 7th 11/17/22 Largest borrow rate increases among liquid names
Earnings	Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 SNY Sanofi $47.22 / -1.505 (-3.09%) IFRS EPS for Q4 was EUR… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Erasca upgraded to Overweight from Equal Weight at Morgan Stanley » 05:51 02/03/23 02/03 05:51 02/03/23 05:51 ERAS Erasca $4.16 / +0.165 (+4.13%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Syndicate On The Fly ERAS Erasca $4.16 / +0.165 (+4.13%) 12/20/22 Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/13/22 Erasca announces FDA clearance of IND application for ERAS-3490 12/09/22 Erasca announces pricing of underwritten offering of common stock 12/09/22 Erasca, Novartis enter worldwide license agreement for naporafenib ERAS Erasca $4.16 / +0.165 (+4.13%) 11/09/22 Erasca reports Q3 EPS (29c), consensus (31c) 09 Dec ERAS Erasca $4.16 / +0.165 (+4.13%) 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning

Downgrade	Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley » 05:50 02/03/23 02/03 05:50 02/03/23 05:50 CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 01/19/23 Cyteir Therapeutics announces prioritization of CYT-0851 development 08/08/22 Cyteir Therapeutics expects cash to fund operations into second half of 2024 CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral from Buy at BofA 01/20/23 JPMorgan Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan 09/09/22 Morgan Stanley Cyteir downgraded at Morgan Stanley with time needed for data CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 11/07/22 Cyteir Therapeutics reports Q3 EPS (31c), consensus (41c) 08/08/22 Cyteir Therapeutics reports Q2 EPS (34c), consensus (44c)
Downgrade	Meta Platforms downgraded to Reduce from Hold at HSBC » 05:48 02/03/23 02/03 05:48 02/03/23 05:48 META Meta Platforms $188.78 / +35.675 (+23.30%) HSBC analyst Nicolas… HSBC analyst Nicolas Cote-Colisson downgraded Meta Platforms to Reduce from Hold with an unchanged price target of $110. The company's Q4 results showed higher engagement, but revenue was still down, the analyst tells investors in a research note. The firm says headwinds for the company include the macro environment, competition and regulation versus one "longer-term tailwind that is Meta's lead in Metaverse." The recent share rally leads HSBC to downgrade the shares to Reduce. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B 02/01/23 Meta says 2023 will be 'a year of efficiency' 02/01/23 Meta Platforms announces $40B increase in share repurchase authorization 02/01/23 Meta Platforms reports FoA and RL segment restructuring charges META Meta Platforms $188.78 / +35.675 (+23.30%) 05:13 Today DZ Bank Meta Platforms upgraded to Hold from Sell at DZ Bank 02/02/23 Deutsche Bank Meta Platforms price target raised to $200 from $125 at Deutsche Bank 02/02/23 RBC Capital Meta Platforms price target raised to $225 from $160 at RBC Capital 02/02/23 Needham Meta Platforms reported fundamentals still deteriorating, says Needham META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B 02/01/23 Meta Platforms reports Q4 EPS $1.76, consensus $2.22 02/01/23 Notable companies reporting after market close 11/09/22 Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 FTC denies Meta request to bar Khan from antitrust case, Bloomberg says 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Meta wins approval over FTC to acquire Within Unlimited, Bloomberg says 02/01/23 Meta debates on whether to share Reel money with creators, Information reports META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Earnings season driving record option volume 02/02/23 Early notable gainers among liquid option names on February 2nd 02/02/23 Notable open interest changes for February 2nd 02/01/23 Meta Platforms (Facebook) options imply 8.9% move in share price post-earnings
Periodicals	Tesla's sales of China-made EVs up 10% y/y in January, Reuters reports » 05:44 02/03/23 02/03 05:44 02/03/23 05:44 TSLA Tesla $188.32 / +7.05 (+3.89%) Tesla sold 66,051… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TSLA Tesla $188.32 / +7.05 (+3.89%) 01/31/23 Tesla sees capex of $6.0B-$8.0B in 2023 and $7B-9B in 2024 and 2025 01/31/23 Tesla asked for documents on driver assist systems by DOJ 01/25/23 Tesla extends afterhours gains, up over 5% at $152.45 01/25/23 Tesla CEO says Dojo AI to be competitive with Nvidia at end of 2023 TSLA Tesla $188.32 / +7.05 (+3.89%) 01/30/23 Bernstein Bernstein sees orders as 'most critical' to Tesla stock 01/30/23 Berenberg Tesla upgraded to Buy from Hold at Berenberg 01/26/23 Morgan Stanley Tesla FY23 earnings could bottom near $3 per share, says Morgan Stanley 01/26/23 Wedbush Tesla price target raised to $200 from $175 at Wedbush TSLA Tesla $188.32 / +7.05 (+3.89%) 01/25/23 Tesla reports Q4 EPS $1.19, consensus $1.13 01/25/23 Notable companies reporting after market close 10/19/22 Tesla reports Q3 EPS $1.05, consensus 99c 10/19/22 Notable companies reporting after market close TSLA Tesla $188.32 / +7.05 (+3.89%) 02/01/23 Tesla to ramp up Shanghai production, Reuters reports 01/31/23 Tesla considering plant near new Mexico City airport, Reuters reports 01/30/23 Twitter starts applying for U.S. state licenses in payment master plan, FT says 01/30/23 Tesla faces owner backlash after big price cuts, WSJ reports TSLA Tesla $188.32 / +7.05 (+3.89%) 02/02/23 What You Missed On Wall Street This Morning 01/31/23 What You Missed On Wall Street On Tuesday 01/30/23 What You Missed On Wall Street On Monday 01/30/23 What You Missed On Wall Street This Morning TSLA Tesla $188.32 / +7.05 (+3.89%) 02/02/23 Notable open interest changes for February 2nd 02/01/23 Notable open interest changes for February 1st 01/31/23 Notable open interest changes for January 31st 01/30/23 Notable open interest changes for January 30th
Downgrade	Stifel downgrades C.H. Robinson to Hold after 'sizable miss' » 05:43 02/03/23 02/03 05:43 02/03/23 05:43 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) Stifel analyst J. Bruce… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson sees 2023 capital expenditures $90M-$100M 01/03/23 C.H. Robinson CEO Bob Biesterfeld steps down, Scott Anderson named interim CEO 11/17/22 C.H. Robinson raises quarterly dividend to 61c per share from 55c 11/02/22 C.H. Robinson sees $175M of gross cost savings in Q4 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 05:22 Today Stifel C.H. Robinson downgraded to Hold from Buy at Stifel 02/02/23 BMO Capital C.H. Robinson price target lowered to $85 from $90 at BMO Capital 02/02/23 Susquehanna C.H. Robinson price target raised to $86 from $83 at Susquehanna 02/02/23 Wells Fargo C.H. Robinson price target raised to $95 from $86 at Wells Fargo CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson reports Q4 adjusted EPS $1.03, consensus $1.38 02/01/23 Notable companies reporting after market close 11/02/22 C.H. Robinson reports Q3 EPS $1.78, consensus $2.17 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 01/10/23 C.H. Robinson reaches standstill agreement with Ancora, WSJ reports CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 Fly Intel: After-Hours Movers 01/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/15/22 Fly Intel: After-Hours Movers CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 CH Robinson Worldwide options imply 6.1% move in share price post-earnings
Downgrade	RBC downgrades Spirit AeroSystems on supply chain issues » 05:40 02/03/23 02/03 05:40 02/03/23 05:40 SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) RBC Capital analyst Ken… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 11/07/22 Spirit AeroSystems rises 13.1% 10/19/22 Spirit AeroSystems enters MOU with Joramco for MRO services cooperation 09/21/22 Spirit AeroSystems enters MOU with MAB to develop MRO services for 737 aircraft 09/20/22 Spirit AeroSystems SEAS joint venture to open in October SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 05:08 Today RBC Capital Spirit AeroSystems downgraded to Sector Perform from Outperform at RBC Capital 01/09/23 Truist Spirit AeroSystems price target raised to $42 from $39 at Truist 11/11/22 BofA BofA double downgrades '737 story' Spirit AeroSystems to Underperform 11/11/22 BofA Spirit AeroSystems downgraded to Underperform from Buy at BofA SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 11/03/22 Spirit AeroSystems reports Q3 EPS (15c), consensus (40c) 11/02/22 Notable companies reporting before tomorrow's open 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Spirit AeroSystems reports Q2 adjusted EPS ($1.21), consensus (24c) SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 11/11/22 What You Missed On Wall Street On Friday 11/11/22 What You Missed On Wall Street This Morning 11/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/08/22 What You Missed On Wall Street On Thursday 02/15/23 44th Annual Aerospace/Defense & Industrials Conference 02/07/23 Spirit AeroSystems - SPR SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 12/29/22 Largest borrow rate increases among liquid names
Upgrade	Publicis upgraded to Overweight from Equal Weight at Barclays » 05:24 02/03/23 02/03 05:24 02/03/23 05:24 PUBGY Publicis $19.20 / +0.822 (+4.47%) Barclays analyst Julien… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research PUBGY Publicis $19.20 / +0.822 (+4.47%) 10/18/22 Chicken Soup teams with Publicis' APX Content Ventures on new reality series PUBGY Publicis $19.20 / +0.822 (+4.47%) 01/31/23 Barclays Publicis price target raised to EUR 68 from EUR 62.50 at Barclays 01/06/23 UBS Publicis price target raised to EUR 71 from EUR 68 at UBS 12/16/22 Morgan Stanley Publicis price target raised to EUR 53 from EUR 50 at Morgan Stanley 12/12/22 JPMorgan Publicis price target raised to EUR 82 from EUR 75 at JPMorgan
Downgrade	C.H. Robinson downgraded to Hold from Buy at Stifel » 05:22 02/03/23 02/03 05:22 02/03/23 05:22 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) Stifel analyst J. Bruce… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson sees 2023 capital expenditures $90M-$100M 01/03/23 C.H. Robinson CEO Bob Biesterfeld steps down, Scott Anderson named interim CEO 11/17/22 C.H. Robinson raises quarterly dividend to 61c per share from 55c 11/02/22 C.H. Robinson sees $175M of gross cost savings in Q4 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/02/23 BMO Capital C.H. Robinson price target lowered to $85 from $90 at BMO Capital 02/02/23 Susquehanna C.H. Robinson price target raised to $86 from $83 at Susquehanna 02/02/23 Wells Fargo C.H. Robinson price target raised to $95 from $86 at Wells Fargo 02/02/23 Bernstein C.H. Robinson price target lowered to $92 from $110 at Bernstein CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson reports Q4 adjusted EPS $1.03, consensus $1.38 02/01/23 Notable companies reporting after market close 11/02/22 C.H. Robinson reports Q3 EPS $1.78, consensus $2.17 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 01/10/23 C.H. Robinson reaches standstill agreement with Ancora, WSJ reports CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 Fly Intel: After-Hours Movers 01/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/15/22 Fly Intel: After-Hours Movers CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 CH Robinson Worldwide options imply 6.1% move in share price post-earnings
Downgrade	Sallie Mae downgraded to Equal Weight from Overweight at Wells Fargo » 05:20 02/03/23 02/03 05:20 02/03/23 05:20 SLM Sallie Mae $14.82 / -2.965 (-16.67%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly SLM Sallie Mae $14.82 / -2.965 (-16.67%) 01/10/23 Sallie Mae names Kerri Palmer as COO SLM Sallie Mae $14.82 / -2.965 (-16.67%) 01/10/23 JPMorgan Sallie Mae price target raised to $18 from $17 at JPMorgan 01/06/23 Barclays Sallie Mae price target raised to $22 from $20 at Barclays 11/11/22 Compass Point Sallie Mae downgraded to Neutral at Compass Point following outperformance 11/10/22 Compass Point Sallie Mae downgraded to Neutral from Buy at Compass Point SLM Sallie Mae $14.82 / -2.965 (-16.67%) 02/01/23 Sallie Mae sees FY23 adjusted EPS $2.50-$2.70, consensus $2.58 02/01/23 Sallie Mae reports Q4 EPS (33c), consensus 47c 10/26/22 Sallie Mae sees FY22 revenue $2.50-$2.60, consensus $2.64 10/26/22 Sallie Mae reports Q3 EPS 29c, consensus 48c SLM Sallie Mae $14.82 / -2.965 (-16.67%) 12/01/22 Supreme Court keeps Biden student debt relief plan on hold, Bloomberg says 12/01/22 Supreme Court keeps Biden student debt relief plan on hold, Bloomberg says 08/24/22 Biden cancels $10,000 of student loan debt, $20,000 in Pell Grants 08/24/22 Biden to forgive $10,000 in student loans, $20,000 Pell debt, Bloomberg says SLM Sallie Mae $14.82 / -2.965 (-16.67%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 08/24/22 What You Missed On Wall Street On Wednesday 08/24/22 What You Missed On Wall Street This Morning
Downgrade	Cognizant downgraded to Neutral from Outperform at Baird » 05:19 02/03/23 02/03 05:19 02/03/23 05:19 CTSH Cognizant $70.62 / +1.78 (+2.59%) Baird analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options CTSH Cognizant $70.62 / +1.78 (+2.59%) 02/02/23 Cognizant raises dividend 7% to 29c 01/26/23 Cognizant, CoreLogic announce new 10-year services agreement worth $1B 01/23/23 Cognizant to acquire Mobica, terms not disclosed 01/12/23 Cognizant appoints Ravi Kumar S as CEO CTSH Cognizant $70.62 / +1.78 (+2.59%) 01/19/23 MoffettNathanson Cognizant downgraded to Underperform from Market Perform at MoffettNathanson 01/15/23 UBS Cognizant price target raised to $68 from $62 at UBS 01/13/23 BMO Capital Cognizant price target raised to $71 from $65 at BMO Capital 01/09/23 BofA Cognizant downgraded to Underperform from Neutral at BofA CTSH Cognizant $70.62 / +1.78 (+2.59%) 02/02/23 Cognizant sees Q1 revenue $4.71B-$4.76B, consensus $4.88B 02/02/23 Cognizant reports Q4 adjusted EPS $1.01, consensus $1.02 02/02/23 Notable companies reporting after market close 01/12/23 Cognizant now sees Q4 revenue $4.8B vs. prior $4.72B-$4.77B view CTSH Cognizant $70.62 / +1.78 (+2.59%) 02/02/23 Fly Intel: After-Hours Movers 01/21/23 Buy/Sell: Wall Street's top 10 stock calls this week 01/19/23 What You Missed On Wall Street On Thursday 01/19/23 What You Missed On Wall Street This Morning CTSH Cognizant $70.62 / +1.78 (+2.59%) 01/12/23 Early notable gainers among liquid option names on January 12th 01/11/23 Largest borrow rate increases among liquid names
Upgrade	Lundin Mining upgraded to Overweight from Equal Weight at Morgan Stanley » 05:19 02/03/23 02/03 05:19 02/03/23 05:19 LUNMF Lundin Mining $7.32 / -0.28 (-3.68%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research LUNMF Lundin Mining $7.32 / -0.28 (-3.68%) 10/13/22 Sandstorm Gold provides update on royalty portfolio LUNMF Lundin Mining $7.32 / -0.28 (-3.68%) 02/02/23 Credit Suisse Lundin Mining price target raised to C$10.25 from C$8.25 at Credit Suisse 01/23/23 JPMorgan Lundin Mining price target lowered to SEK 57 from SEK 65 at JPMorgan 01/18/23 Scotiabank Lundin Mining price target raised to C$15 from C$12 at Scotiabank 01/17/23 Scotiabank Lundin Mining price target lowered to C$9 from C$10 at Scotiabank

Downgrade	Aptiv downgraded to Peer Perform from Outperform at Wolfe Research » 05:16 02/03/23 02/03 05:16 02/03/23 05:16 APTV Aptiv $118.67 / +3.97 (+3.46%) Wolfe Research analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTV Aptiv $118.67 / +3.97 (+3.46%) 12/23/22 Aptiv completes acquisition of Wind River from TPG 12/15/22 Aptiv appoints Benjamin Lyon as CTO 11/14/22 Appaloosa exits positions in Kohl's, Occidental Petroleum, Micron 09/13/22 Aptiv to acquire Intercable Automotive Solutions for EUR595M APTV Aptiv $118.67 / +3.97 (+3.46%) 01/23/23 Deutsche Bank Aptiv named short-term buy idea at Deutsche Bank 01/19/23 Deutsche Bank Deutsche Bank keeps Buy on Aptiv, lowers price target to $126 01/09/23 BofA Aptiv downgraded to Neutral from Buy at BofA 12/15/22 RBC Capital Aptiv price target lowered to $115 from $120 at RBC Capital APTV Aptiv $118.67 / +3.97 (+3.46%) 02/02/23 Aptiv sees FY23 adjusted EPS $4.00-$4.50, consensus $4.73 02/02/23 Aptiv reports Q4 adjusted EPS $1.27, consensus $1.22 11/03/22 Aptiv backs FY22 adjusted EPS view $3.05-$3.55, consensus $3.16 11/03/22 Aptiv reports Q3 adjusted EPS $1.28, consensus 99c APTV Aptiv $118.67 / +3.97 (+3.46%) 01/27/23 Early notable gainers among liquid option names on January 27th 08/05/22 Largest borrow rate increases among liquid names
Upgrade	Meta Platforms upgraded to Hold from Sell at DZ Bank » 05:13 02/03/23 02/03 05:13 02/03/23 05:13 META Meta Platforms $188.78 / +35.675 (+23.30%) DZ Bank analyst Ingo… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B 02/01/23 Meta says 2023 will be 'a year of efficiency' 02/01/23 Meta Platforms announces $40B increase in share repurchase authorization 02/01/23 Meta Platforms reports FoA and RL segment restructuring charges META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Deutsche Bank Meta Platforms price target raised to $200 from $125 at Deutsche Bank 02/02/23 RBC Capital Meta Platforms price target raised to $225 from $160 at RBC Capital 02/02/23 Needham Meta Platforms reported fundamentals still deteriorating, says Needham 02/02/23 Jefferies Meta Platforms price target raised to $225 from $175 at Jefferies META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B 02/01/23 Meta Platforms reports Q4 EPS $1.76, consensus $2.22 02/01/23 Notable companies reporting after market close 11/09/22 Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 FTC denies Meta request to bar Khan from antitrust case, Bloomberg says 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Meta wins approval over FTC to acquire Within Unlimited, Bloomberg says 02/01/23 Meta debates on whether to share Reel money with creators, Information reports META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Earnings season driving record option volume 02/02/23 Early notable gainers among liquid option names on February 2nd 02/02/23 Notable open interest changes for February 2nd 02/01/23 Meta Platforms (Facebook) options imply 8.9% move in share price post-earnings
Downgrade	ING Groep downgraded to Hold from Buy at Societe Generale » 05:13 02/03/23 02/03 05:13 02/03/23 05:13 ING ING Groep $13.87 / -0.77 (-5.26%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings ING ING Groep $13.87 / -0.77 (-5.26%) 12/30/22 ING completes share buyback program, to pay remaining EUR 297M to holders 11/03/22 ING Groep on track to meet previously communicated financial targets 11/03/22 ING Groep director Mariana Gheorghe decides not to stand for reappointment 11/03/22 ING Groep announces share buyback programme of up to EUR 1.5B ING ING Groep $13.87 / -0.77 (-5.26%) 01/27/23 Barclays ING Groep price target raised to EUR 12.50 from EUR 11.50 at Barclays 12/06/22 JPMorgan ING Groep price target raised to EUR 13.40 from EUR 13 at JPMorgan 11/18/22 Morgan Stanley ING Groep price target raised to EUR 16 from EUR 14 at Morgan Stanley 11/18/22 Morgan Stanley ING Groep price target raised, named a 'Top Pick' at Morgan Stanley ING ING Groep $13.87 / -0.77 (-5.26%) 02/02/23 ING Groep reports Q4 net result per share EUR 0.30 vs. EUR 0.25 last year 11/03/22 ING Groep reports Q3 net result per share EUR 0.26 vs EUR 0.35 last year 08/04/22 ING Groep reports Q2 net result per share EUR 0.31 vs. EUR 0.11 last year
Downgrade	Kesko downgraded to Hold from Buy at Danske Bank » 05:12 02/03/23 02/03 05:12 02/03/23 05:12 KKOYY Kesko $11.47 / -0.64 (-5.28%) Danske Bank analyst Calle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KKOYY Kesko $11.47 / -0.64 (-5.28%) 01/24/23 DNB Markets Kesko initiated with a Buy at DNB Markets
Upgrade	EMS-Chemie upgraded to Buy from Hold at Kepler Cheuvreux » 05:11 02/03/23 02/03 05:11 02/03/23 05:11 EMSHF EMS-Chemie $670.30 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EMSHF EMS-Chemie $670.30 / + (+0.00%) 12/13/22 Berenberg EMS-Chemie price target raised to CHF 600 from CHF 590 at Berenberg 12/13/22 Stifel EMS-Chemie downgraded to Hold from Buy at Stifel 10/31/22 Berenberg EMS-Chemie downgraded to Hold from Buy at Berenberg 10/18/22 Baader Helvea EMS-Chemie downgraded to Reduce from Add at Baader Helvea

Events

Earnings calls, analyst events, roadshows and more

AVTR
Today at 08:00

Avantor - AVTR Conference Calls
TWST
Today at 08:00

Twist Bioscience - TWST Conference Calls
SNY
Today at 08:00

Sanofi - SNY Conference Calls
Today at 08:30

Employment Situation: Private Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Manufacturing Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Participation Rate: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Non-Farm Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings Y/Y: January 2023 Government Event
Today at 08:30

Employment Situation--Unemployment Rate: January 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	VERA X VERA Vera Therapeutics Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LIFC Priced at: $7.00 14.286M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ALGM X ALGM Allegro MicroSystems Block Trade Managers: Credit Suisse Priced at: $38.00 4.98M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GPCR X GPCR Structure Therapeutics IPO Managers: Jefferies, SVB Securities, Guggenheim & BMO Capital Priced at: $15.00 10.74M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ROIV X ROIV Roivant Sciences Secondary Managers: Goldman Sachs, SVB Securities, Cowen & Cantor Fitzgerald Priced at: $7.50 26.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AVTX X AVTX Avalo Therapeutics Spot Secondary Managers: SVB Securities & RBC Capital Priced at: $3.98 3.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDBL X EDBL Edible Garden Spot Secondary Managers: Maxim & Joseph Gunnar Priced at: $6.30 1.62M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	WULF X WULF TeraWulf Spot Secondary Managers: JonesResearch $1.03
Thurs	ASST X ASST Asset Entities IPO Managers: Boustead $5.00 1.5M Shares SODR X SODR Sondors IPO Managers: DA Davidson & Lake Street $8.00 - 10.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDXH X MDXH MDxHealth Secondary Managers: Cowen & William Blair, BTIG, KBCS $6.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CLLS X CLLS Cellectis Spot Secondary Managers: Jefferies & Barclays $3.26 22M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TWO X TWO Two Harbors Spot Secondary Managers: Goldman Sachs, JPMorgan & Citi, JMP Securities $17.80-18.00 10M Shares
Fri	No deals

View All Syndicate Announcements »

Allete downgraded to Sell from Neutral at Guggenheim

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access